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Abstract
© 2018  The  Author(s).  The  aim  of  this  work  was  to  examine  a  possible  role  of  clot
contraction/retraction in thrombotic complications of systemic lupus erythematosus (SLE). Using
a novel automated method, we investigated kinetics of clot contraction in the blood of 51 SLE
patients and 60 healthy donors. The functionality of platelets in the SLE patients was assessed
using flow cytometry by expression of P-selectin and fibrinogen-binding capacity. The rate and
degree of clot contraction were significantly reduced in SLE patients compared with healthy
subjects,  especially  in  the patients  with  higher  blood levels  of  anti-dsDNA antibodies.  The
reduced platelet contractility correlated with partial refractoriness of platelets isolated from the
blood of SLE patients to stimulation induced by the thrombin receptor activating peptide. To test
if the anti-dsDNA autoantibodies cause continuous platelet activation, followed by exhaustion
and dysfunction of the cells, we added purified exogenous anti-dsDNA autoantibodies from SLE
patients to normal blood before clotting.  In support of  this hypothesis,  the antibodies first
enhanced clot contraction and then suppressed it in a time-dependent manner. Importantly, a
direct correlation of clot contraction parameters with the disease severity suggests that the
reduced compactness of intravascular clots and thrombi could be a pathogenic factor in SLE that
may exaggerate the impaired blood flow at the site of thrombosis. In conclusion, autoantibodies
in SLE can affect platelet contractility, resulting in reduced ability of clots and thrombi to shrink
in volume, which increases vessel obstruction and may aggravate the course and outcomes of
thrombotic complications in SLE.
http://dx.doi.org/10.1042/cs20171510
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